Overview

To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration

Status:
Completed
Trial end date:
2016-10-24
Target enrollment:
Participant gender:
Summary
This is a Phase 1, first-in-human (FIH) single ascending dose study being conducted to better understand the safety, tolerability and pharmacokinetics of AZD5634 in healthy subjects
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca